BioAlliance Pharma Presents Additional US Pivotal Phase III Results on Loramyc(TM) (Miconazole Lauriad(R)) at the 47Th Annual Meeting of the IDSA

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).

MORE ON THIS TOPIC